title: Effect of treatment with 4-hydroxyandrostenedione on the peripheral conversion of androstenedione to estrone and in vitro tumor aromatase activity in postmenopausal women with breast cancer.
abstract: The effect of treatment with the aromatase inhibitor, 4-hydroxyandrostenedione (4-OHA) on the peripheral conversion of androstenedione to estrone has been examined in eight postmenopausal women with advanced breast cancer. Before treatment conversion of androstenedione to estrone ([p]AEIBB) ranged from 0.81 to 3.7% and was almost completely inhibited after treatment with 4-OHA (two doses of 500 mg i.m. with an interval of 12 days between doses). Transfer constants were also measured by the urinary method ([p]AEIBU) for some subjects and decreased from 2.3 +/- 0.52% to 0.24 +/- 0.11% after treatment, a mean reduction of 90%. Mean plasma concentration of estradiol (37.4 +/- 16.6 pmol/liter) and estrone (99.0 +/- 32.2 pmol/liter) decreased significantly (P less than 0.01) to 15.7 +/- 4.6 pmol/liter and 52.4 +/- 8.9 pmol/liter, respectively, after treatment. Aromatase and DNA polymerase alpha (a marker of cell proliferation) activities were measured in seven samples of breast tumor tissue obtained before and after treatment. For three samples there was a marked (67 +/- 17%) decrease in tumor aromatase activity after treatment, for two, little change occurred, while tumor aromatase activity in the other two samples appeared to be resistant to the effect of 4-OHA. The correlation between tumor aromatase and DNA polymerase alpha activities (r = 0.45) failed to reach a significant level.
authors.affiliation: Department of Chemical Pathology, St. Mary's Hospital Medical School, London.
authors.forename: M J
authors.initials: MJ
authors.lastname: Reed
authors.forename: L C
authors.initials: LC
authors.lastname: Lai
authors.forename: A M
authors.initials: AM
authors.lastname: Owen
authors.forename: A
authors.initials: A
authors.lastname: Singh
authors.forename: N G
authors.initials: NG
authors.lastname: Coldham
authors.forename: A
authors.initials: A
authors.lastname: Purohit
authors.forename: M W
authors.initials: MW
authors.lastname: Ghilchik
authors.forename: N A
authors.initials: NA
authors.lastname: Shaikh
authors.forename: V H
authors.initials: VH
authors.lastname: James
mesh_terms: D000368:Aged; D000735:Androstenedione / Q000031:analogs & derivatives* / Q000378:metabolism* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001141:Aromatase / Q000378:metabolism*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000378:metabolism; D004257:DNA Polymerase II / Q000378:metabolism; D004970:Estrone / Q000378:metabolism*; D005260:Female; D006801:Humans; D007700:Kinetics; D008657:Metabolic Clearance Rate
chemical_list: D000970:Antineoplastic Agents; D004970:Estrone; D000735:Androstenedione; D001141:Aromatase; D004257:DNA Polymerase II; C014594:formestane